Article

Genetic Testing for Women at High Risk for Breast and Ovarian Cancers

Debu Tripathy, editor-in-chief of CURE magazine and breast oncologist, discusses genetic testing from the 32nd annual Miami Breast Cancer Conference.

Debu Tripathy, editor-in-chief of CURE magazine and breast oncologist, discusses genetic testing from the 32nd annual Miami Breast Cancer Conference.

The two most common genes that increase risk of breast cancer is BRCA1 and BRCA2. The debate now is should we screen individuals based on family history and not after a cancer diagnosis.

Those who are diagnosed with breast cancer under age 45, we recommend genetic counseling before proceeding with genetic testing for BRCA1 or BRCA2. Individuals who have a strong family history of ovarian cancer and male breast cancer also should discuss genetic testing with a counselor.

However, individuals who undergo genetic testing and discover they do not have a BRCA mutation, doesn't necessarily mean they do not have a genetic predisposition to breast and ovarian cancers, as there are other genetic mutations that can increase the risk of these cancers.

"One of the developments that have occurred with next-generation sequencing is that we can not only look for BRCA 1 and 2, but we can look across the entire genome and identify other genes that have recently been associated with an increase risk of breast cancer," he says. "Although we know less about these genes."

Panel testing would allow physicians, particularly with patients who have a strong family history but who do not have a BRCA mutation, to find out what is causing that possible familial association, he says.

"It's critical that patients get genetic counseling, not just testing in the doctor's office," he says.

Genetic counselors have the expertise to talk, not only about the science behind it, but the emotional issues and patient choice issues and the preferences that go into making this important decision, he says.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content